The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11045 results:
Author Title [ Type(Asc)] Year
Journal Article
Bakirtzi, K., Papadimitriou I., Vakirlis E., Lallas A., & Sotiriou E. (2023).  Photodynamic Therapy for Field Cancerization in the Skin: Where Do We Stand?. Dermatol Pract Concept. 13(4), 
Sotiriou, E., Koussidou-Eremonti T., Chaidemenos G., APALLA Z., & Ioannides D. (2010).  Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial.. Acta Derm Venereol. 90(2), 216-7.
Trakatelli, M., Charalampidis S., Novakovic L. B., Patsatsi A., Kalabalikis D., & Sotiriadis D. (2009).  Photodermatoses with onset in the elderly.. Br J Dermatol. 161 Suppl 3, 69-77.
Verrou, K-M., Galliou P. Angeliki, Papaioannou M., & Koliakos G. (2019).  Phosphorylation mapping of Laminin β1-chain: Kinases in association with active sites.. J Biosci. 44(2), 
Galliou, P. Angeliki, Verrou K-M., & Koliakos G. (2019).  Phosphorylation mapping of laminin α1-chain: Kinases in association with active sites.. Comput Biol Chem. 80, 480-497.
Pafili, Z., Maridaki M., Giannaki C. D., Karatzaferi C., Liakopoulos V., Eleftheriadis T., et al. (2019).  Phosphorus nutritional knowledge among dialysis health care providers and patients: A multicenter observational study.. Clin Nutr ESPEN. 31, 33-37.
Ioannides, D., Lazaridou E., Apalla Z., & Devliotou-Panagiotidou D. (2009).  Phosphodiesterase-5 inhibitors and rosacea: report of 10 cases.. Br J Dermatol. 160(3), 719-20.
Hatzimouratidis, K., & Hatzichristou D. G. (2009).  Phosphodiesterase type 5 inhibitors: unmet needs.. Curr Pharm Des. 15(30), 3476-85.
Hatzimouratidis, K., Burnett A. L., Hatzichristou D., McCullough A. R., Montorsi F., & Mulhall J. P. (2009).  Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.. Eur Urol. 55(2), 334-47.
Hatzimouratidis, K. (2009).  Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms?. Expert Opin Investig Drugs. 18(3), 245-54.
Papa, A., Kontana A., & Tsergouli K. (2015).  Phlebovirus infections in Greece.. J Med Virol. 87(7), 1072-6.
Youssef, B., Pavlou G., & Tsiridis E. (2014).  Philadelphia 2013: international consensus meeting on periprosthetic joint infection.. Hip Int. 24(1), 3-4.
Chatzizisis, Y. S., Ziakas A., Feloukidis C., Paramythiotis D., Hadjimiltiades S., Iliadis A., et al. (2014).  Pheochromocytoma crisis presenting with cardiogenic shock.. Herz. 39(1), 156-60.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., & Harsoulis F. (2007).  Pheochromocytoma: an update on genetics and management.. Endocr Relat Cancer. 14(4), 935-56.
Boutou, A. K., Pitsiou G. G., Siakka P., Dimitroulas T., Paspala A., Sourla E., et al. (2016).  Phenotyping Exercise Limitation in Systemic Sclerosis: The Use of Cardiopulmonary Exercise Testing.. Respiration. 91(2), 115-23.
Abouzeid, H., Balmer A., Moulin A. P., Mataftsi A., Zografos L., & Munier F. L. (2012).  Phenotypic variability of retinocytomas: preregression and postregression growth patterns.. Br J Ophthalmol. 96(6), 884-9.
Hilgert, N., Huentelman M. J., Thorburn A. Q., Fransen E., Dieltjens N., Mueller-Malesinska M., et al. (2009).  Phenotypic variability of patients homozygous for the GJB2 mutation 35delG cannot be explained by the influence of one major modifier gene.. Eur J Hum Genet. 17(4), 517-24.
Papadimas, G. Konstantin, Kekou K., Papadopoulos C., Kararizou E., Kanavakis E., & Manta P. (2015).  Phenotypic variability and molecular genetics in proximal myotonic myopathy.. Muscle Nerve. 51(5), 686-91.
Katsikis, I., Karkanaki A., Misichronis G., Delkos D., Kandaraki E. A., & Panidis D. (2011).  Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.. Eur J Obstet Gynecol Reprod Biol. 156(2), 181-5.
Koiou, E., Dinas K., Tziomalos K., Toulis K., Kandaraki E. A., Kalaitzakis E., et al. (2011).  The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria.. Obes Facts. 4(2), 145-50.
Papadaniil, C. D., Kosmidou V. E., Tsolaki A., Tsolaki M., Kompatsiaris I. Yiannis, & Hadjileontiadis L. J. (2015).  Phase-amplitude cross-frequency coupling in EEG-derived cortical time series upon an auditory perception task.. Conf Proc IEEE Eng Med Biol Soc. 2015, 4150-3.
Crown, J. P., Diéras V., Staroslawska E., Yardley D. A., Bachelot T., Davidson N., et al. (2013).  Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.. J Clin Oncol. 31(23), 2870-8.
Molife, L. R., Attard G., Fong P. C., Karavasilis V., Reid A. H. M., Patterson S., et al. (2010).  Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).. Ann Oncol. 21(1), 109-13.
Argiris, A., Karamouzis M. V., Gooding W. E., Branstetter B. F., Zhong S., Raez L. E., et al. (2011).  Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.. J Clin Oncol. 29(9), 1140-5.
Fountzilas, G., Fragkoulidi A., Kalogera-Fountzila A., Nikolaidou M., Bobos M., Calderaro J., et al. (2010).  A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.. Cancer Chemother Pharmacol. 65(4), 649-60.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.